Industry
Oncology market research
Treatment paradigm, biomarker and launch research across solid and haematological tumours.
HealthcareMarketResearch runs oncology market research for global leaders, challengers and investors. Our 5,000+ researchers include practising clinicians, procurement leaders, payers and former executives from the oncology industry.
Studies combine expert calls, qualitative interviews and quantitative surveys, so you can size the opportunity, understand stakeholders and plan go-to-market with confidence.
Topics we research
- Line of therapy
- Biomarker testing
- Tumour board dynamics
- Patient journeys
Relevant services
At a glance
Oncology market research at a glance
The audiences, methods and timelines a typical oncology study runs on.
- Audiences
- Medical, radiation and surgical oncologists, haemato-oncologists, molecular pathologists, oncology pharmacists, tumour board chairs, oncology nurses and patient advocacy leads
- Typical methods
- Expert calls, patient chart and record reviews, treatment pathway interviews, tumour board influence mapping, oncologist surveys and advisory boards
- Research focus
- line of therapy · biomarker testing · tumour board dynamics · patient journeys
- Geography
- 100+ Indian cities, metro and tier 2, plus global peer benchmarks
- Expert matching
- 24–48 hours from a confirmed brief
- Fieldwork window
- 5–10 business days for most interview and survey studies
- Core outputs
- Line-of-therapy maps, biomarker testing pathways, regimen selection drivers, named KOL and tumour board lists and patient journey friction points
- Regulatory context
- Studies reflect current treatment guidelines and CDSCO, FDA and EMA labelling, with off-label questioning governed by EphMRA and BHBIA codes.
Scope, sample and timings are confirmed in writing before fieldwork starts.
Why teams commission it
Decisions oncology research supports
Each brief starts from the decision it has to inform, so the readout answers the question your team is actually facing.
Line-of-therapy positioning
Where a regimen realistically sits by line, and which patients oncologists would move to it first.
Biomarker testing pathway
Who orders which test, when results arrive and how turnaround gaps change the treatment actually given.
Regimen and combination choice
How combinations, sequencing and tolerability trade-offs are weighed against current standard of care.
Tumour board influence
Who shapes the recommendation in multidisciplinary discussion, and which evidence carries weight in the room.
Funding and access route
What hospital formularies, payers and patient assistance routes will support, and where cost stops a prescription.
Patient journey intervention
Where diagnosis, referral and treatment initiation stall, and which fixes would shorten time to therapy.
Stakeholders
Who we reach in oncology
We recruit the people who make and influence the decision — not only the easiest audience to find. Every expert is screened for recency of practice and conflicts of interest.
Treating oncology teams
- Medical oncologists and haemato-oncologists
- Radiation and surgical oncologists
- Oncology pharmacists and day-care unit leads
- Oncology nurses and chemotherapy coordinators
Diagnosis and decision forums
- Molecular pathologists and genomics leads
- Tumour board chairs and participants
- Radiologists reporting response assessment
- Guideline and professional society contributors
Access and support
- Hospital formulary and P&T committee members
- Payer medical directors and HTA assessors
- Patient advocacy and support group leads
- Patient assistance programme managers
How it runs
A oncology research programme, stage by stage
Senior researchers at our Pune, Maharashtra, India headquarters design, moderate and analyse every study.
- 01
Tumour and pathway framing
We define the tumour type, line of therapy and biomarker population in scope, then build the oncologist and pathology sample around real case volume.
Scoped in writing
- 02
Oncology recruitment
We recruit treating oncologists, pathologists and tumour board participants, screened on patient volume, setting and recency of practice.
24–48 hours
- 03
Pathway interviews and chart work
Interviews, surveys and record-based exercises map actual treatment decisions, with adverse event and off-label rules built into each guide.
5–10 business days
- 04
Treatment paradigm readout
We deliver line-of-therapy maps, biomarker and testing dependencies, access barriers and the influence map behind decisions.
Report and debrief
Compliance
Standards every oncology study runs under
Compliance is designed into the screener and the guide, not bolted on at the end.
Research codes
oncology guides follow EphMRA, BHBIA and Insights Association standards, including adverse event and off-label handling.
Regulatory framing
Studies reflect current treatment guidelines and CDSCO, FDA and EMA labelling, with off-label questioning governed by EphMRA and BHBIA codes.
Data protection
Recruitment, transcripts and data files are handled under GDPR, HIPAA and India's DPDP Act, with pseudonymised outputs.
Conflict screening
Every expert is screened for employer restrictions, confidentiality obligations and conflicts of interest before a session is confirmed.
FAQs
Oncology market research questions
What is oncology market research?+
Oncology market research is primary research with oncologists, pathologists, pharmacists and tumour board members on how cancer is diagnosed, treated and funded. HealthcareMarketResearch covers line of therapy, biomarker testing, tumour board dynamics and patient journeys.
Can you reach oncologists across tumour types?+
Yes. We recruit medical, radiation, surgical and haemato-oncologists across solid and haematological tumours in 100+ Indian cities, from tertiary cancer centres to private practice, screened on patient volume.
How do you research biomarker testing pathways?+
We interview the oncologists who order tests and the molecular pathologists who run them, covering test selection, panel versus single-gene choices, turnaround time and how often results arrive too late to change therapy.
Can you run chart or patient record reviews?+
Yes. Record-based exercises are run in de-identified form with consenting clinicians, so treatment patterns reflect documented decisions rather than recall, under professional research codes and data protection law.
Do you map oncology KOLs and tumour boards?+
Yes. We map clinical opinion leaders, guideline contributors and tumour board participants, documenting the public basis for inclusion so medical affairs teams can plan engagement compliantly.
Coverage
Where we run oncology research in India
Studies are designed and analysed at our Pune, Maharashtra, India headquarters, with recruitment and fieldwork across 100+ Indian cities — metro, tier 2 and tier 3.
All industries
Explore the other 24 healthcare segments
Grouped by the kind of organisation or therapy area you work in, so you can find the neighbouring page quickly.
Life sciences companies
Therapy areas
Care delivery, payers and technology
Have a healthcare question that needs real answers?
Brief us today and talk to a verified expert this week.